ImmuCell Corp. (ICCC)
11.25
-0.08
(-0.71%)
USD |
NASDAQ |
Nov 18, 16:00
11.25
0.00 (0.00%)
After-Hours: 20:00
ImmuCell Enterprise Value : 107.09M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 107.09M |
| November 16, 2026 | 107.91M |
| November 13, 2026 | 101.82M |
| November 12, 2026 | 97.00M |
| November 11, 2026 | 96.73M |
| November 10, 2026 | 97.36M |
| November 09, 2026 | 97.00M |
| November 06, 2026 | 93.18M |
| November 05, 2026 | 94.55M |
| November 04, 2026 | 98.36M |
| November 03, 2026 | 97.27M |
| November 02, 2026 | 100.09M |
| October 30, 2026 | 97.36M |
| October 29, 2026 | 97.91M |
| October 28, 2026 | 100.64M |
| October 27, 2026 | 97.36M |
| October 26, 2026 | 97.18M |
| October 23, 2026 | 97.27M |
| October 22, 2026 | 99.00M |
| October 21, 2026 | 99.73M |
| October 20, 2026 | 99.09M |
| October 19, 2026 | 99.64M |
| October 16, 2026 | 101.82M |
| October 15, 2026 | 100.09M |
| October 14, 2026 | 101.82M |
| Date | Value |
|---|---|
| October 13, 2026 | 102.18M |
| October 12, 2026 | 91.36M |
| October 09, 2026 | 93.18M |
| October 08, 2026 | 92.73M |
| October 07, 2026 | 92.18M |
| October 06, 2026 | 94.73M |
| October 05, 2026 | 92.73M |
| October 02, 2026 | 92.73M |
| October 01, 2026 | 91.36M |
| September 30, 2026 | 93.18M |
| September 29, 2026 | 93.86M |
| September 28, 2026 | 93.32M |
| September 25, 2026 | 93.73M |
| September 24, 2026 | 94.14M |
| September 23, 2026 | 94.32M |
| September 22, 2026 | 94.32M |
| September 21, 2026 | 95.59M |
| September 18, 2026 | 93.96M |
| September 17, 2026 | 94.23M |
| September 16, 2026 | 90.87M |
| September 15, 2026 | 90.59M |
| September 14, 2026 | 91.78M |
| September 11, 2026 | 93.05M |
| September 10, 2026 | 93.64M |
| September 09, 2026 | 93.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
| Arrowhead Pharmaceuticals, Inc. | 6.282B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.9525M |
| Revenue (Quarterly) | 8.04M |
| Total Expenses (Quarterly) | 7.087M |
| EPS Diluted (Quarterly) | 0.1024 |
| Gross Profit Margin (Quarterly) | 44.22% |
| Profit Margin (Quarterly) | 11.85% |
| Earnings Yield | 1.79% |
| Operating Earnings Yield | 2.73% |
| Normalized Earnings Yield | 2.274 |